

Special Issue

Challenges, Limitations and Advancement of Vaccines and Adjuvants

Message from the Guest Editor

Dear Colleagues and Friends, Vaccination is a process of introducing foreign antigenic (better with immunogenic) epitopes to target host in a form of whole bacteria or viruses (inactivated or attenuated), proteins, or nucleotides to eventually induce protective memory responses in the host. Adjuvant is essentially required to improve the efficacy of vaccine via enhancing the host immune responses. The main action mechanism of the adjuvants is to improve immunogenicity of antigen presenting cells to induce memory responses in T cells and B cells, resulting in a long-term protection against target pathogen. The current Special issue entitled 'Challenges, limitations and advancement of vaccines and adjuvants' focuses on the platform and technologies (i.e., material science and synthetic biology), target delivery, and a formulation of vaccine and adjuvant, maximizing their protective immune responses, and validation of the vaccines. Furthermore, the articles in relation to future prospecting, preparedness, efficacy, reactogenicity, validation and advancement of vaccines and adjuvants together with their limitations and challenges are all welcome.

Guest Editor

Prof. Dr. Cheol-Heui Yun

Department of Agricultural Biotechnology, College of Agriculture and Life Sciences, Seoul National University, Seoul 08826, Korea

Deadline for manuscript submissions

closed (31 December 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/86975

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).